Literature DB >> 23599593

Multivariate analysis of various factors affecting background liver and mediastinal standardized uptake values.

Manohar Kuruva1, Bhagwant Rai Mittal, Mohammed Labeeb Abrar, Raghava Kashyap, Anish Bhattacharya.   

Abstract

PURPOSE OF THE STUDY: Standardized uptake value (SUV) is the most commonly used semi-quantitative PET parameter. Various response assessment criteria grade the tumor uptake relative to liver or mediastinal uptake. However various factors can affect the background SUV values. This prospective study was carried out to assess the variability of liver and mediastinal SUVs normalized to lean body mass (SUL-L, SUL-M), body surface area (SUB-L, SUB-M), and body weight (SUW-L, SUW-M) and their dependence on various factors which can affect SUV values.
MATERIALS AND METHODS: Eighty-eight patients who underwent F-18 FDG PET/CT for various oncological indications were prospectively included in this study. SUVs of liver and mediastinum were calculated by ROIs drawn as suggested by Wahl, et al., in PERCIST 1.0 criteria. Multivariate linear regression analysis was done to assess for the various factors influencing the SUVs of liver and mediastinum. Factors assessed were age, sex, weight, blood glucose level, diabetic status, and uptake period. A P value less than 0.01 was considered significant.
RESULTS: SUL-L, SUL-M, SUB-L, SUB-M, SUW-L, SUW-M were not affected significantly by age, sex, blood glucose levels, diabetic status. The uptake period had a statistically significant effect on SUL-L (P = 0.007) and SUW-L (P = 0.008) with a progressive decrease with increasing uptake time. Body weight showed a statistically significant effect on SUW-L (P = 0.001) while SUL-L and SUB-L were not dependent on weight. SUB-L was least dependent on weight (P = 0.851) when compared with SUL-L (P = 0.425). However SUL-L was also not affected statistically significantly by variations in body weight (P = 0.425). Mediastinal SUVs were not significantly affected by any of the factors.
CONCLUSIONS: As mediastinal SUVs are not affected significantly by any of the factors, it can be considered as background when wide variations occur in uptake times or weight of the patient when comparing two PET/CT studies to evaluate response.

Entities:  

Keywords:  F-18 FDG PET/CT; liver SUV; mediastinal SUV; standardized uptake value (SUV)

Year:  2012        PMID: 23599593      PMCID: PMC3628256          DOI: 10.4103/0972-3919.108835

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


INTRODUCTION

The interpretation of PET images includes qualitative analysis and quantitative analysis. Visual interpretation is susceptible to inter- and intraobserver variabilities[1] and defining thresholds to predict the outcomes on the basis of visual analysis only may not be possible. Quantitative analysis can overcome these limitations. Quantitative methods include absolute quantitation and semiquantitative methods. Absolute quantitative methods use Patlak analysis, nonlinear regression analysis, etc.,[2-4] However these require dynamic imaging and are cumbersome and not feasible to be practiced in day-to-day practice. Standardized uptake value (SUV), a semiquantitative parameter, most commonly employed in clinical practice is easy to be obtained but depends on various factors.[5] Determination of background SUV of liver and mediastinal blood pool is important as the response assessment criteria like PERCIST 1.0,[6] International Harmonisation Project (IHP),[7] and London criteria[89] grade the tumor uptake relative to liver or mediastinal blood pool activity. Recent studies have also shown the importance of liver background SUV values in determining the threshold to define the positive interim PET study to predict progression.[10] With an aim toward standardizing methods of assessing the response, Wahl, et al.,[6] have proposed PERCIST criteria as a standardized method of defining the region of interest (ROI) for measuring liver SUV and have suggested the usage of SUV of liver normalized to lean body mass as a measure to define tumor uptake threshold above which it can be defined as measurable disease. However no prospective study has evaluated further the reliability of determining the background liver uptake according to recommendations suggested by PERCIST criteria. In light of the above, this prospective study was carried to assess the variability of liver and mediastinal SUVs normalized to lean body mass (SUL-L, SUL-M), body surface area (SUB-L, SUB-M), and body weight (SUW-L, SUW-M) and their dependence on various factors which can affect SUV values.

MATERIALS AND METHODS

Eighty-eight patients who had undergone F-18 FDG PET/CT for various oncological indications were prospectively included in this study. Patients with obvious or suspicious involvement of liver by tumor on PET/CT studies were excluded from the study. Liver SUV values were determined by drawing a 3 cm-diameter three-dimensional ROI placed on the normal right lobe of liver as recommended in PERCIST 1.0 criteria.[6] Mediastinal SUV values were determined by drawing an ROI over contiguous slices on descending aorta carefully excluding the walls from the ROI. Factors assessed were age, sex, weight, blood glucose level at the time of injection of F-18 FDG, diabetic status and uptake period. Multivariate linear regression analysis was applied to assess the significance of various factors influencing the SUVs of liver and mediastinum according to the normalization factors applied. A P value less than 0.01 was considered statistically significant.

RESULTS

Of the 88 patients included in this study 48 were females and 40 males. Mean age was 50.28 ± 17.43 years (range 14-87 years). Mean weight was 58.5 ± 13.26 kg (range = 33-93 kg). Blood glucose levels at the time of injection of F-18 FDG were 115.8 ± 26.43 (range = 68-177 mg/dl). Twelve of the 88 patients included were diabetic and the blood glucose levels in diabetics ranged from 88-177 with a mean of 126 mg/dl. The mean uptake period was 75.92 ± 19.75 (range = 51-160 minutes) with a median of 77 minutes. SUL-L, SUW-L, SUB-L, SUL-M, SUW-M, SUB-M ranged from 1.2 to 2.8 (mean 1.85), 1.5 to 3.5 (mean 2.31), 0.4 to 0.9 (mean 0.61), 0.7 to 2.1 (mean 1.45), 0.5 to 3.1 (mean 171), 0.2 to 0.7 (mean 0.48) respectively. SUL-L, SUL-M, SUB-L, SUB-M, SUW-L, SUW-M were not affected significantly by age, sex, blood glucose levels, diabetic status. The uptake period had a statistically significant effect on SUL-L (P = 0.007; range = 1.2-2.8) and SUW-L (P = 0.008; range = 1.5-3.5) with progressive decrease with increasing uptake time. Body weight showed a statistically significant effect on SUW-L (P = 0.001; range = 1.5-3.5) while SUL-L and SUB-L were not dependent on weight. SUB-L was least dependent on weight (P = 0.851, range = 0.5-0.9) when compared with SULL (P = 0.425). However SUL-L also was not significantly affected by variations in body weight (P = 0.425). Mediastinal SUVs were not significantly affected by bodyweight when normalized to bodyweight, body surface area of lean body mass. All the results are depicted in Table 1.
Table 1

The significance (P values) of various factors affecting standardized uptake values normalized by different methods

The significance (P values) of various factors affecting standardized uptake values normalized by different methods

DISCUSSION

Two types of interpretations namely visual and quantitative analyses are often used in clinical practice to interpret response to therapy with PET or PET/CT. Visual analysis is more commonly used and is relatively easy. However, visual analysis alone may be inadequate to interpret PET/CT during response assessment and has a major disadvantage of high interobserver variability. To observe and estimate the response of tumors to various chemotherapy and radiotherapy regimens it is essential to quantify or establish thresholds using semiquantitative parameters. Thresholds can also be obtained by comparing with background tissues like mediastinum and liver as suggested by London criteria.[89] Also to define measurable disease on PET studies determination of background SUV values is necessary.[6] Thus it is essential that these background SUV values do not vary significantly between patients and also with various factors to obtain meaningful assessment of response assessment according to various criteria. Many studies have previously evaluated the factors affecting the SUV values one of which is the method of ROI selection.[11-16] Almost all of the above studies have evaluated the variability of tumoral SUV values. Only few studies have evaluated the variability and factors influencing background SUV values.[17-22] PERCIST criteria proposed by Wahl, et al.,[6] have standardized the method to draw ROIs to determine the background liver SUL. In our study the same method was used and only SUWL was found to be significantly affected by weight with increasing values with increasing weight and this is in corroboration with previous studies.[2223] However SUL-L and SUB-L were not significantly affected by weight. This is again in concordance with previous studies.[2223] Scan time had significant correlation with SUW-L, SUB-L, SUL-L with decreasing values with time. This might be explained by the fact that liver has abundance of enzyme glucose-6-phoshphatase causing continuous glycolysis and decrease in FDG retention.[24] It is necessary to obtain the follow-up scans during the same period of uptake time to minimize overdiagnosing of the residual disease. In comparison mediastinal SUV values did not vary with any of the factors affecting SUV values of liver, i.e., weight and scan time. This is an important observation and mediastinal SUV values can be used as background in preference over liver background in overweight patients or when the scan times varies from pretherapy to post therapy scan. Other factors like age, sex, diabetic status, and blood glucose levels at the time of injection of the tracer did not have significant effect on SUV values of liver and blood pool. Though it can be argued that variations of liver SUV can be minimal, this can be significant when calculating the measurable tumor uptake by formula of 1.5 × liver SUV with values reaching up to 2-4 thereby affecting the reliability of response assessment by PET/CT. When compared by different normalization methods SUB-L values were least affected by all the factors studied but the values were small ranging from 0.5 to 0.8 which might make it difficult to be used for response assessment as small fluctuations of 30%, i.e., 0.2 can occur with minimal variations in acquisition parameters and other technical factors. SUL values appear to be close to SUV-W values and reasonably less affected by various factors except for scan time in case of liver. So it is essential that all the scan times should be within same time limits between pretherapy and follow-up scans.

CONCLUSION

To conclude though SUB-L appears to be least dependent on weight, SUL-L is also not significantly affected by weight and has higher values close to SUW-L. However the uptake period appears to be the only factor which affects SUL-L significantly and this calls for acquisition of scans with standard uptake period with minimal variability in uptake times even when image interpretation does not require quantitation. In contrast mediastinal SUVs were not affected significantly by any of the factors and when normalized by any of the methods and can be used for definition of background when wide variations occur in scan times or in heavily obese patients.
  23 in total

1.  Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?

Authors:  David A Mankoff; Mark Muzi; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2003 Sep-Oct       Impact factor: 3.488

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

Review 3.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 4.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods.

Authors:  C J Hoekstra; I Paglianiti; O S Hoekstra; E F Smit; P E Postmus; G J Teule; A A Lammertsma
Journal:  Eur J Nucl Med       Date:  2000-06

5.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

6.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.

Authors:  A Stahl; K Ott; M Schwaiger; W A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-15       Impact factor: 9.236

8.  Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five PET scanners.

Authors:  Yasuyuki Takahashi; Noboru Oriuchi; Hidenori Otake; Keigo Endo; Kenya Murase
Journal:  Ann Nucl Med       Date:  2008-08-01       Impact factor: 2.668

9.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.

Authors:  C K Kim; N C Gupta; B Chandramouli; A Alavi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

10.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  9 in total

1.  Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Authors:  Mohd Hafizi Mahmud; Abdul Jalil Nordin; Fathinul Fikri Ahmad Saad; Ahmad Zaid Fattah Azman
Journal:  Quant Imaging Med Surg       Date:  2015-10

2.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

3.  Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects.

Authors:  Yuan Cao; Ke Zhou; Wei Diao; Xipeng Long; Fangfang Tian; Minggang Su; Zhiyun Jia
Journal:  Quant Imaging Med Surg       Date:  2021-01

4.  Concurrent Low Brain and High Liver Uptake on FDG PET Are Associated with Cardiovascular Risk Factors.

Authors:  Hyun-Yeol Nam; Sungmin Jun; Kyoungjune Pak; In Joo Kim
Journal:  Korean J Radiol       Date:  2017-02-07       Impact factor: 3.500

Review 5.  Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review.

Authors:  Clarice Sprinz; Stephan Altmayer; Matheus Zanon; Guilherme Watte; Klaus Irion; Edson Marchiori; Bruno Hochhegger
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240

Review 6.  Impacts of time interval on 18F-FDG uptake for PET/CT in normal organs: A systematic review.

Authors:  Rang Wang; Haotian Chen; Chengzhong Fan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

7.  Intrapatient variability of 18F-FDG uptake in normal tissues.

Authors:  Mohamed Hosny Mohamed Sayed; Aya Km Abdelnaim; Nsreen Ra Mohamadien
Journal:  J Clin Imaging Sci       Date:  2022-07-08

8.  Factors that affect PERCIST-defined test-retest comparability: an exploration of feasibility in routine clinical practice.

Authors:  Hui Yuan; Daniel King Hung Tong; Varut Vardhanabhuti; Pek-Lan Khong
Journal:  Clin Nucl Med       Date:  2015-12       Impact factor: 7.794

Review 9.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.